Verrica Pharmaceuticals Inc. — Revenue by Fiscal Year
5 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/347b291f-9da3-4d39-b59a-eb84388beb43/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2025 | $35.6M | 2025-01-01 – 2025-12-31 | evidence 0001660334-26-000008 |
| FY 2024 | $7.6M | 2024-01-01 – 2024-12-31 | evidence 0001660334-26-000008 |
| FY 2023 | $5.1M | 2023-01-01 – 2023-12-31 | evidence 0000950170-24-022659 |
| FY 2022 | $9.0M | 2022-01-01 – 2022-12-31 | evidence 0000950170-23-006118 |
| FY 2021 | $12.0M | 2021-01-01 – 2021-12-31 | evidence 0000950170-22-002685 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Verrica Pharmaceuticals Inc. — all facts · Net Income · Operating Income